Evergreening strategies delay market entry for generic medicines to the detriment of the Australian community and there is a lack of evidence to support extending market exclusivity for pharmaceuticals, according to the Productivity Commission’s draft report into Australia’s intellectual property arrangements. The report's release has been welcomed by the Generic and Biosimilar Medicines Association. “The
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.